Directa Plus PLC (LON:DCTA, AIM:DCTA, OTC:DTPKF) said it has continued to perform strongly since its trading update in June, with all verticals delivering a “robust” first-half performance.
As a results, the producer of graphene nanoplatelets-based products expects revenues for the six months to 30 June 2022 to have grown by around 39% to €5.5mln.
For the full year, revenue is expected to increase by more than 40% from last year’s figure of €8.6mln, Directa Plus said in a statement.
The company said it continues to generate interest from global players despite the uncertain macro-economic climate caused by the war in Ukraine, inflation and recession fears.
Rising inflation led to cost increases and reduced margins in the first half, it noted. It has invested in manufacturing equipment which should deliver productivity gains and margin efficiencies in the second half, that will “materially reduce” direct production costs.
Giulio Cesareo, founder and CEO of Directa Plus, commented: "We are pleased with the growth and commercial progress we have achieved in the first half of the year.
"Directa Plus continues to gain momentum in this uncertain and challenging market and continues to make progress to commercialise our highly valuable IP portfolio.
“The fundraise completed in December 2021 has allowed us to accelerate growth, reduce production costs, and to develop the pipeline where we see many exciting opportunities."
The company said it still awaits the final decision on the award of a significant tender in Romania for its Environmental Remediation services, adding that it continues to believe that it is well positioned to win the tender.